Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE followed by FOLFOX hepatic arterial infusion chemotherapy plus sorafenib for intermediate and advanced primary liver cancer
ChiCTR2000030303Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: overall survival. Started Jan 2012; status: completed.
02
Drugs
sorafeniboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000030303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030303.